Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. That followed an analyst's inclusion of the company on a top-shelf list of stock picks for next year.

Before market open, Cowen prognosticator Joshua Jennings tapped Abbott as a Best Idea for 2023. In doing so, he reiterated his outperform (buy, in other words) recommendation on the stock and $130 per share price target.

Jennings' rosy view on Abbott is based on the consensus estimates for 2023.

Continue reading

Source Fool.com